KalVista Pharmaceuticals, Inc. financial data

Symbol
KALV on Nasdaq
Industry
Pharmaceutical Preparations
Location
55 Cambridge Parkway, Suite 901 E, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
April 30
Former names
Carbylan Therapeutics, Inc. (to 11/21/2016), Carbylan Biosurgery, Inc (to 1/3/2013), Carbylan Biosurgery Inc (to 12/29/2005)
Latest financial report
Q4 2023 - Mar 11, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 840 % -47.5%
Return On Equity -86.1 % -60.8%
Return On Assets -72.7 % -50.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.2 M shares +23.5%
Common Stock, Shares, Outstanding 34.6 M shares +1.37%
Entity Public Float 120 M USD -68.4%
Common Stock, Value, Issued 34 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 34.7 M shares +22.8%
Weighted Average Number of Shares Outstanding, Diluted 34.7 M shares +22.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 84.9 M USD +12.4%
General and Administrative Expense 38.8 M USD +27.7%
Operating Income (Loss) -124 M USD -16.8%
Nonoperating Income (Expense) 15.4 M USD +1.16%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -92.9 M USD -12.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -108 M USD -19.4%
Earnings Per Share, Basic -3.12 USD/shares +12.6%
Earnings Per Share, Diluted -3.12 USD/shares +12.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.1 M USD -72.9%
Assets, Current 104 M USD -45.8%
Property, Plant and Equipment, Net 2.42 M USD -20.2%
Operating Lease, Right-of-Use Asset 7.05 M USD -13%
Other Assets, Noncurrent 397 K USD +102%
Assets 114 M USD -44%
Accounts Payable, Current 3.1 M USD +82.6%
Employee-related Liabilities, Current 5.47 M USD +32.7%
Accrued Liabilities, Current 14.8 M USD +67.7%
Liabilities, Current 19.1 M USD +64.8%
Operating Lease, Liability, Noncurrent 6.26 M USD -15.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.29 M USD +6.98%
Retained Earnings (Accumulated Deficit) -425 M USD -34.2%
Stockholders' Equity Attributable to Parent 88.6 M USD -52%
Liabilities and Equity 114 M USD -44%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26.7 M USD -17.5%
Net Cash Provided by (Used in) Financing Activities 204 K USD +21.4%
Net Cash Provided by (Used in) Investing Activities 19.6 M USD -34.7%
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 34.6 M shares +1.37%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.83 M USD -196%
Deferred Tax Assets, Valuation Allowance 45.3 M USD +60.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 47 M USD +57.9%
Operating Lease, Liability 8.23 M USD +0.54%
Payments to Acquire Property, Plant, and Equipment 6 K USD -99.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -108 M USD -17.6%
Lessee, Operating Lease, Liability, to be Paid 9.26 M USD -16.7%
Property, Plant and Equipment, Gross 5.91 M USD +28.5%
Operating Lease, Liability, Current 1.19 M USD +12.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.81 M USD +0.95%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.78 M USD +0.91%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.31 M USD -16.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.85 M USD +0.93%
Deferred Tax Assets, Operating Loss Carryforwards 35.8 M USD +54.1%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.85 M USD -1.39%
Operating Lease, Payments 1.62 M USD +25.5%
Depreciation, Depletion and Amortization 193 K USD +22.2%
Deferred Tax Assets, Net of Valuation Allowance 1.76 M USD +11.7%
Share-based Payment Arrangement, Expense 3.25 M USD +23.2%